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A B S T R A C T   
The management of aggressive breast cancer, particularly, triple negative breast cancer (TNBC) remains a 
formidable challenge, despite treatment advancement. Although newer therapies such as atezolizumab, olaparib, 
and sacituzumab can tackle the breast cancer prognosis and/or progression, but achieved limited survival benefit 
(s). The current research efforts are aimed to develop and implement strategies for improved bioavailability, 
targetability, reduce systemic toxicity, and enhance therapeutic outcome of FDA-approved treatment regimen. 
This review presents various nanoparticle technology mediated delivery of chemotherapeutic agent(s) for breast 
cancer treatment. This article also documents novel strategies to employ cellular and cell membrane cloaked 
(biomimetic) nanoparticles for effective clinical translation. These technologies offer a safe and active targeting 
nanomedicine for effective management of breast cancer, especially TNBC.   
1. Introduction 
Breast cancer (BC) remains the most commonly diagnosed cancer 
among women and is the second leading cause of death after lung cancer 
in the United States [1]. In 2020, it was estimated that 276,480 new 
cases of BC will be diagnosed among women and 42,170 women will be 
expected to die due to this disease. Breast cancer begins when the ma-
lignant epithelial cells accumulate and grow out. Depending on the re-
gion they grow out from, it is classified into non-invasive and invasive. 
Non-invasive (carcinoma in-situ) is when the carcinoma is confined in 
the lobules and duct. Invasive carcinomas occur when the carcinoma 
diffuses to the surrounding connective tissues and metastasize to distant 
sites. These carcinomas are divided into ductal and lobular carcinoma, 
depending on where the tumor is formed. Ductal carcinomas comprise 
two-third of the total BC and arise from the epithelial cells of the ducts, 
whereas the lobular carcinoma arises from the lobules and is about 
one-third of the total BC cases [2]. 
Triple negative breast cancer (TNBC) represents the most aggressive 
and heterogeneous subtype of BC. Clinically, it is characterized by 
negative for expression of estrogen receptor (ER), progesterone receptor 
(PR), and human epidermal growth factor receptor 2 (HER2) protein. 
Typically, TNBC demonstrates an increased mitotic activity, increased 
expression of proliferation markers, high nuclear atypia, high nuclear- 
cytoplasmic ratio, scant stromal content, central necrosis, multiple 
apoptotic cells, invasive, and stromal lymphocytic infiltration [3,4]. 
Additionally, these tumors are also characterized by rapid growth rate, 
higher grade, greater chance of lymph node involvement/progression, 
and metastasize mostly to the viscera, especially the lungs and the brain 
[5]. The distinct cellular phenotype, aggressive nature, metastatic po-
tential, and lack of receptor or target [6], makes chemotherapy as a 
prefered treatment option for TNBC. However, TNBC with the worst 
prognosis and high recurrence rate within the first 5 years of therapy 
and shorter overall survival to only 9–13 months [7], in contrast to other 
subtypes of BC, which makes therapeutic intervention for TNBC is an 
unmet need. 
2. Therapeutic strategies for TNBC 
As described above, TNBC due to heterogeneity, molecular vari-
ability, and stemness [8] has no specific treatment protocol. Although 
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the relentless efforts of researchers have led to improvements in the 
therapy of TNBC, and newer targets are discovered by studying the 
genomic variability. Therapies that have shown promising outcomes in 
TNBC, either alone or in combination with neoadjuvant therapy have 
been evaluated by clinical trials, are summarized below. Fig. 1 describes 
the schematic representation of the various conventional treatment 
strategies and emerging treatment trends for TNBC. Although chemo-
therapy remains the backbone treatment option for most TNBC patients, 
emerging trends are evolved which includes immunotherapy (check-
point inhibitors), targeted therapy (inhibitors of various pathways), 
antibody conjugates, and novel nanotherapeutic formulation. 
2.1. Conventional chemotherapy 
Chemotherapy remains the mainstay treatment for TNBC. These 
agents are usually anthracycline, platinum, and/or taxanes. Anthracy-
clines such as doxorubicin (DOX) and epirubicin (EP) have shown 
enhanced response rate and survival by 22 months [9–12]. These agents 
have proven to be beneficial and have shown enhanced sensitivity when 
used as a single agent [10,11] as well as in neoadjuvant setting [12]. 
Phase III clinical trial of anthracyclines as an adjuvant agent versus CMF 
(cyclophosphamide, CP; methotrexate, MTX; and 5-fluorouracil, 5-FU) 
[13] demonstrates a 23% decrease in the recurrence rate. A 17% path-
ological complete response (PCR) in Phase II clinical trial was observed 
in a neoadjuvant setting with anthracyclines agents in combination with 
others such as CP, 5-FU, and epirubicin (ER) [14]. A Phase III clinical 
trial demonstrate that a 5-year disease-free survival was achieved in 
71% of the TNBC patients treated thrice every week in contrast to only 
26% improvement with treated twice weekly when anthracyclines are 
used in combination [15–17]. Although, a higher response rate is ach-
ieved with this therapy [16,17] yet higher recurrence rate and overall 
low survival rate [18] has limited usage of this type of therapy. Other 
associated side effects include acute toxicity such as irreversible car-
diotoxicity myelotoxicity, alopecia, nausea, and vomiting [18–20]. 
Platinum agents have proven to be beneficial for the treatment of 
TNBC patients when used in combination or as single agents [21]. These 
agents are effective in patients with a breast cancer gene (BRCA) mu-
tation. A Phase II clinical trial (NCT00148694) suggests that 21% of 
patients received PCR with single-agent cisplatin and 15% response 
when excluding the BRCA1 mutations. This indicates the importance of 
platinum agents as adjuvant or neoadjuvant therapy in BRCA mutants 
[10]. BRCA1 mutant has shown increased sensitivity to platinum agents 
because of the ability to repair DNA; however, it may become resistant 
and may be required to be used in homologous combination [11]. 
Another Phase II clinical trial suggests carboplatin and paclitaxel (PTX) 
with or without trastuzumab showed a 67% increase in PCR [22]. In 
another Phase II clinical trial, cisplatin (CIS) combination with ER and 
5-FU in addition to PTX versus without the PTX treatment improved the 
response rate by 40% [23]. A higher response rate of 34% was observed 
in women treated with platinum and docetaxel (DTX) [24]. Thus, a 
combination of platinum agents has been shown to have higher efficacy 
than when used alone. Therapy with platinum agents are of special in-
terest when treating a TNBC patient with a BRCA defect. 
Taxanes either as a single agent or in combination with anthracy-
clines have shown to be beneficial in TNBC in contrast to other subtypes 
of BC, attaining PCR of up to 40% [25]. Cancer and Leukemia Group B 
Fig. 1. Schematic illustration of various treatment strategies for TNBC. Conventional strategies with chemotherapeutic agents (doxorubicin, paclitaxel, and 
cisplatin), targeted strategies includes specific pathway inhibitors, immunotherapies, and nanotechnology (drug loaded nanoparticles or antibody drug conjugates). 
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(CALGB) team conducted a trial on 9344 subjects, demonstrate 
disease-free survival among TNBC patients treated with PTX, versus all 
other subtypes of BC [26]. BC International Research Group (BCIRG) 
reported a clinical trial report that indicated an advantage in the group 
that was co-treated with PTX over cyclophosphamide on the TNBC 
cohort [27]. Further, a non–platinum-based neoadjuvant therapy with 
CP-DOX-vincristine-prednisolone shows a 15% increase in the PCR in 
comparison to all the other regimen, suggesting TNBC apart BRCA 
mutation subset, has greater response to taxanes in comparison to other 
regimens [28]. 
2.2. Targeted therapies 
The molecular heterogeneity of TNBC [6] makes it difficult for 
physicians and clinicians to have a standard care guided approach for 
the treatment. Advancement in the molecular classification and genome 
sequencing has led to the development of targeted therapy [6,8]. From a 
variety of gene expression analysis, six main subtypes of TNBC have 
been proposed, viz. basal-like 1, basal-like 2, immunomodulatory, 
mesenchymal, mesenchymal stem-like, and luminal androgen receptor 
(AR) [29]. Numerous clinical trials are underway to develop targeted 
therapy for TNBC using inhibitors of poly ADP ribose polymerase 
(PARP), phosphatidylinositol 3-kinase/Protein kinase B (PI3K/AKT), 
mitogen-activated protein kinases (MAPK), and cyclin-Dependent Ki-
nase (CDK). 
Among these therapies, PARP-1 inhibitor(s) leads to enhanced DNA 
double-strand breaks causing an increase in apoptosis [30–32]. PARP-1 
inhibitor has been particularly beneficial in BRCA1 and BRCA2 mutant 
cells because of their ability to sensitize cells [31,32]. Although BRCA 
mutations account for only 20% of TNBC population, yet several PARP 
inhibitors have gained clinical approval such as olaparib, veliparib, 
niraparib, rucaparib, and talazoparib. Phase III clinical trial in TNBC 
patients with BRCA mutation report that oral PARP inhibitor olaparib 
increases the progression-free survival to 7 months in contrast to 4.2 
months in the placebo group. US Food and Drug Administration (FDA) 
approved the first PARP inhibitor (olaparib in 2018) for the treatment of 
advanced-stage BRCA mutant TNBC [33]. Talazoparib treatment 
confirmed that about 53% of patients achieved PCR in a phase II clinical 
trial NCT02282345 [34]. A larger single-arm Phase II study 
(NCT03499353) proved that talazoparib is highly effective in HER2 
negative advanced BC with an overall survival of 24.3 months, in 
contrast to only 6.3 months in patients receiving only chemotherapy. 
This lead to the approval of the second PARP inhibitor for germline 
BRCA mutation [34]. 
The PI3K/AKT regulates cell growth and glucose metabolism. There 
are complexities associated with the activated PI3K/AKT pathway, 
although activated PI3K/AKT pathway is high in TNBC [34]. Ipatasertib, 
an oral AKT inhibitor is used with PTX demonstrated improved 
progression-free survival from 9 months to 4.9 months in TNBC patients 
(phase II NCT02162719) [35] and improvement in overall survival of 
23.1 months versus 18.4 months [36]. Inhibition of epidermal growth 
factor receptor (EGFR), a transmembrane tyrosine kinase receptor by 
PI3K/AKT pathway has proven to be useful in the treatment of TNBC. 
However, cetuximab a humanized monoclonal antibody used in com-
bination with other taxanes failed to show significant improvement in 
the TNBC subtype [37]. Similarly, another phase II multicenter clinical 
trial by the Translational BC Research Consortium demonstrates that 
cetuximab used alone or in combination with platinum agents such as 
cisplatin and carboplatin, failed to show any impressive result by the 
anti-EGFR antibody [38]. This is probably because only 50% of the 
TNBC cases are EGFR positive [39]. 
AR accounts for 13–37% among TNBC patients and it is more prev-
alent among older [40,41] people. However, the role of AR as a prog-
nostic marker in TNBC is not clear, as there are contradictory reports 
about the characteristics of AR in TNBC. It is also associated with low 
nuclear grade, and low proliferative rate and is unrelated to be a 
prognostic marker [42], whereas some suggest they have a higher nu-
clear grade, high lymph node metastasis, and higher mortality rate [43]. 
Enzalutamide is a novel targeted AR inhibitor that competitively binds 
to the AR and prevents translocation to the nucleus [44]. NCT02750358 
is a Phase II ongoing clinical trial for determining the compliance rate of 
enzalutamide as adjuvant therapy for a 1-year dose [45]. In another 
Phase II clinical trial, superior benefits are achieved with enzalutamide 
indicating this may be a therapeutic option for patients. To further 
evaluate the efficiency of enzalutamide with PTX a phase IIB is currently 
ongoing. Bicalutamide also an AR inhibitor, has shown to have prom-
ising results in a phase III clinical trial for metastatic TNBC patients [46]. 
The role of activation MAPK was initially investigated in vitro, which 
causes loss or downregulation of various genetic and epigenetic func-
tions that are associated with chemoresistance. MEK inhibitors are 
known to cause efficient suppression of chemoresistance either alone or 
in combination with other chemotherapeutic drugs. Significant inhibi-
tory effects were seen with combination treatment of cobimetinib with 
PTX [47]. Another study demonstrates, MEK inhibitor selumetinib given 
in combination with either buparlisib or the platelet-derived growth 
factor receptor inhibitor pazopanib, showed effective inhibition of brain 
metastases in TNBC patients [48]. An ongoing clinical trial shows MEK 
inhibitor trametinib in combination with gemcitabine showed complete 
response in the patient with metastatic TNBC [49]. However, there have 
been serious toxicities prohibiting phase II clinical study of MEK in-
hibitor with mTOR or PI3K inhibitors [50,51]. 
CDK is responsible for hyperphosphorylation of retinoblastoma 
protein (RP) and causes G1-S phase transition in the cell cycle [52]. CDK 
inhibitors thus were explored as a potential target for TNBC. Palbociclib 
is a selective inhibitor of CDK and was explored in clinical trials for 
TNBC with positive RP expression, that demonstrated a partial response 
in 50% of the patients, improving disease-free survival for 6 months or 
more [53]. There are several other clinical trials conducted either alone 
or in combination with other chemotherapy. 
2.3. Antibody-drug conjugates 
Antibody-drug conjugates (ADCs) are also considered as targeted 
therapy where the toxic anticancer drug targets the cancer cells through 
the specific binding of an antibody that has specificity for receptors on 
the surface of the cancer cell. There have been lot of ongoing research 
using ADCs for TNBC with some of them discussed below. Trophoblast 
antigen 2 (Trop2) [54] is target via ADC for TNBC. IMMU-132, also 
known as sacituzumab govitecan is an ADC that targets Trop2 and have 
been used in combination with three PARP inhibitor; olaparib, rucaparib 
and talazoparib and have shown improved overall response [55]. 
Another compelling ADC, glembatumumab vedotin that combines the 
monomethyl auristatin E (MMAE) (a potent microtubule-disrupting 
agent) shows improvement in disease-free progression in Phase I/II 
clinical trial [56]. However, data suggests that a 100 mg dose caused 
some toxicity of grade 3 and 4, which may limit the usage of these agents 
[57]. Ladiratuzumab vedotin is another ADC explored for targeting 
TNBC and is composed of a humanized IgG1, MMAE and a monoclonal 
antibody for targeting oestrogen-regulated gene (LIV-1). LIV-1 is over-
expressed in 90% TNBC tumors but is not significantly expressed in 
normal tissues. In a phase I study with ladiratuzumab vedotin a 25% 
overall response rate was achieved. Although there are toxicity issues 
such as alopecia, neutropenia and peripheral neuropathy. Ongoing 
studies are still conducted to evaluate the efficiency of ladiratuzumab 
vedotin as monotherapy or in combination with chemotherapy for TNBC 
[58]. 
2.4. Immunotherapy 
TNBC is known to have the highest mutations among all other types 
of BC. The role of tumor-infiltrating lymphocytes play a major role in 
disease progression in TNBC. Thus, activation of these cytotoxic T cells 
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would be initiating an antitumor immune response. T cells show the 
expression of immune checkpoint inhibitors: cytotoxic T-lymphocyte 
antigen 4 (CTLA-4) and programmed death-1 (PD-1). PD-1 inhibitors are 
the most extensively studied checkpoint and is a cell surface protein 
expressed on the infiltrating tumor lymphocytes that induce inhibition 
of T cells by binding to two ligands: PD-L1 and PD-L2 [59]. Researchers 
are actively involved in evaluating the role of these checkpoint in-
hibitors and have shown some encouraging results for the treatment of 
TNBC. Among PD-1 inhibitors, pembrolizumab was evaluated as a 
first-line therapy in PD-L1 positive TNBC patients. In which 87% of the 
patients had received either neoadjuvant or adjuvant chemotherapy, 
with overall survival outcome being 16.1 months [60]. In another phase 
II trial, I-SPY 2 trial (NCT01042379), 69 HER- and 29 TNBC patients 
were received either neoadjuvant PTX and/or pembrolizumab, followed 
by dose-dependent doxorubicin and cyclophosphamide. The raw PCR 
was improved to 71% with pembrolizumab compared to 19% in the 
control arm, whereas the estimated PCR was 62% with pembrolizumab 
versus 22% in the control arm [60]. The beneficial results achieved 
through I-SPY 2 trial led to the phase III trial, KEYNOTE-552 
(NCT03036488) and KEYNOTE-355 (NCT02819518) which are 
currently ongoing. Another PD-L1 inhibitor that has achieved impress-
ing outcomes among TNBC patients is, atezolizumab. Impassion130 
trial, NCT02425891 which was a phase III trial, among metastatic or 
advanced stage TNBC patients receiving Abraxane with/without atezo-
lizumab plus placebo. A 1.4 fold improvement was achieved among 
patients receiving atezolizumab, with progression-free survival of 2.5 
months, versus 1.7 months who did not receive atezolizumab. Overall 
survival was also improved to 9.5 months, with no significant 
improvement observed among patients without atezolizumab [61]. 
Based on these results, the FDA accelerated the approval of atezolizu-
mab with Abraxane for the treatment of metastatic TNBC patients who 
are PD-L1 positive. Further ongoing phase III trial NCT03125902 is 
being evaluated with patients receiving either atezolizumab and PTX 
versus PTX and placebo for first-line therapy in TNBC. 
Due to the heterogeneity and the inherent nature of TNBC to develop 
multi drug resistance (MDR) to conventional chemotherapeutics, several 
ongoing clinical trials with combination therapies or targeted therapies 
or immunotherapies or ADC, are being evaluated to identify predictable 
biomarkers that will improve treatment outcomes among TNBC pa-
tients. Although, the paradigm is shifting and lots of attention is being 
given to the development of novel and nano-based therapies for TNBC. 
3. Nanotechnology based therapies for TNBC 
The lack of specific (ER, PR, and HER2) cellular receptors on TNBC 
tumors, makes drug delivery to the tumor challenging. So researchers 
are extensively focused on targeted delivery to TNBC. In this regard, 
nanotechnology-based delivery systems have been beneficial to provide 
significant tumor delivery by following active- and passive-targeting 
mechanisms [62]. Passive targeting occurs by a phenomenon known 
as the enhanced permeability and retention (EPR) effect. This phe-
nomenon occurs because of the tumor vasculature that is hyper vascu-
larized with enhanced vascular permeability causing fluid retention and 
lack of lymphatic drainage. This results in extravasation within tumor 
tissues and increased accumulation of therapeutics at the intertumoral 
site, whereas they get cleared into the lymphatic system of healthy tis-
sues [63]. However, achieving therapeutic concentrations inside the 
tumor site is a challenge with passive targeting and, as a result of which 
compromises are usually made on the biotherapeutic window of the 
drug. Active targeting relies on conjugating the surface of the nano-
particle to biocompatible targeting moieties such as aptamers, anti-
bodies, and peptides, that have specificity to the antigens or receptors at 
the tumor site [64,65]. This approach provides a myriad of advantages 
over conventional therapeutic approaches, such as target specific de-
livery, minimizes systemic or non-specific toxicities, increases bio-
distribution and therapeutic window with intravenous administration, 
resulting in transport of maximal payload, improving half-life and sys-
temic circulation, less immunogenic reaction, controlled drug release, 
increase in drug solubility, and stability of poorly water-soluble 
chemotherapeutic agents (which compromises the majority of avail-
able, approved, and marketed chemotherapeutics). Alongside taking 
advanatage of synergistic effects, combined therapy has been able to 
deliver multiple therapeutic agents for multimodal functions, such as 
imaging and/or theranostic agent [66–68]. Some of the commonly 
employed nanoparticles [62] that have been explored for delivery of 
therapeutics are polymeric nanoparticles, micelles, liposomes, den-
drimers, nanoconjugates, albumin nanoparticles, and carbon nanotubes 
(Fig. 2). 
These unique nanostructures can be generated following various 
synthetic methods [69,70]. Hydrothermal, sonochemical, polyol, mi-
crowave synthesis, inert gas condensation, ultrasound, laser ablation, 
thermal decomposition, electrochemical, gamma radiation, spark 
discharge, sputtering, template synthesis, sol-gel, biological building, 
co-precipitation, microemulsion process are commonly used approaches 
to construct these nanostructures [69,71]. It is possible to achieve dry 
nanoparticle powders or nanoparticles dispersed in liquid medium. 
Researchers have employed other techniques such as polymer precipi-
tation, emulsion-solvent diffusion, emulsion-reverse salting out, inter-
facial condensation, polyelectrolyte complexation, ionic gelation and 
many other similar techniques for drug loaded NPs [72]. The super 
critical fluid technology (rapid expansion of supercritical solution, su-
percritical anti solvent, aerosol solvent extraction system, solution 
enhanced dispersion by supercritical fluid, and particles from 
gas-saturated solutions/suspension) is highly considered to generate 
pharmaceutical based particles [73,74]. This new technology overcome 
the drawbacks of spray drying and milling techniques. All these systems 
are further modified for delivering not only drugs but also oligonucle-
otides, DNA or proteins [75]. 
3.1. Polymeric nanoparticles 
Polymeric nanoparticles are nanosized range materials that are 
synthesized using either natural or synthetic biodegradable and 
biocompatible polymers. Depending on the characteristics of the poly-
mer of choice, both hydrophilic and hydrophobic drugs can be encap-
sulated into these nanoparticles that can be released by surface or bulk 
erosion, swelling or diffusion mechanisms. Studies have shown that 
polymeric nanoparticles made of poly(ε-caprolactone)-b-poly(ethyl-
eneglycol)-b-poly(ε-caprolactone) encapsulating DTX successfully 
improved the in vivo survival rate of mice in contrast to marketed 
docetaxel formulation due to the prolonged circulation of the nano-
particles for the EPR effect [76]. Similarly, poly(lactic-co-glycolic 
acid)-poly(ethyleneglycol) nanoparticles were utilized to deliver 
cisplatin in TNBC xenograft mouse model with significant tumor inhi-
bition and prolongation of half-life, although systemic toxicities were 
observed in normal organs such as kidney and liver [77]. 
Inadequate therapeutic dose reaching the tumors via passive tar-
geting has led to the utilization of nanoparticles by decorating the sur-
face with active moieties allowing longer circulation and causing higher 
concentration accumulating in tumor tissues compared to normal tis-
sues. For instance, a novel peptide (Gly–Ile–Arg–Leu–Arg–Gly) conju-
gating onto polymeric nanoparticles containing PTX, exhibited a 
significant delay in tumor growth in contrast to untargeted nano-
particles [78]. A protein polymer called elastin-like polypeptides was 
used to form nanoparticles that assemble into <100 nm and was surface 
decorated with FK506 binding protein 12, which is a cognate receptor 
for potent yet poorly soluble rapamycin (RPM). These nanoparticles 
prolonged circulation time and increased the half-life by 26 folds, with 
enhanced anti-tumor efficacy, and lower cytotoxicity than free drug in 
TNBC xenograft mouse model [79]. Enhancer of zeste homolog 2 (EZH2) 
was found to be overexpressed in TNBC and is found to be responsible 
for poor overall patient survival. Delivery of siRNA via chitosan 
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nanoparticles directed to target the EZH2 in the orthotopic 
MDA-MB-231 mouse model has shown to cause a significant reduction 
in tumor growth [80]. 
3.2. Polymeric micelles 
Polymeric micelles are developed by using hydrophilic and hydro-
phobic chains of polymers, that form Van der Waals bonds to form a 
hydrophobic core which usually encapsulates the drug either by phys-
ical entrapment or chemical bonds. The outer shell on the other hand 
being hydrophilic, aids prolong circulation and prevents rapid clearance 
by the reticuloendothelial system (RES) [81]. A block copolymer of poly 
(ethylene glycol) (PEG) and poly(glutamic acid) conjugated to the active 
metabolite of topoisomerase I inhibitor irinotecan (SN-38) forms ~ 20 
nm spherical polymeric micelles. Significant tumor inhibition in an 
orthotopic mouse model has suggested this could be a promising 
candidate and is in Phase II clinical trial for treatment in TNBC patients 
[82]. Active targeting by polymeric micelles using D-tocopheryl PEG 
succinate polymer, encapsulating DTX conjugated to cetuximab, that 
specifically targets EGFR on the TNBC tumors by 205.6 and 223.8 folds 
in contrast to Taxotere® (marketed formulation of docetaxel) [83]. 
Various polymer micelle-based PTX formulations exist for clinical 
use. Genexol-PM® (Cynviloq™) was developed by Samyang Bio-
pharmaceuticals Corporation (South Korea) for the treatment of several 
types of cancer, such as breast, ovarian cancer, and NSCLC. It is made up 
of monomethoxy-PEG-b-poly(D,L-lactide) diblock copolymer that entraps 
PTX in polymeric micelles (20–50 nm) with a drug loading capacity of 
16.7% w/w. The absence of albumin reduces the risk of microbial 
contamination in comparison to Abraxane. A phase III clinical trial 
(NCT00876486) of the formulation in contrast to the Abraxane in 
metastatic BC, shows enhanced efficacy and reduced toxicity issues 
[84]. Other clinical trials demonstrate that the MTD of this formulation 
was lowered to 180 mg/m2 than that of Abraxane®, although both the 
regimens showed a similar incidence of neutropenia and less severe 
non-hemotoxicity [85,86]. Although, the higher-dose regimen of 390 
mg/m2 has a higher incidence of neutropenia and neuropathy [87]. In 
phase II clinical trial at a dosing regimen of 300 mg/m2 in metastatic BC 
patients, 58.5% of them demonstrate response rates. However, the 
response rate of Taxol® was similar but conducted in a much larger 
group. Also, greater incidence of neutropenia (68.3%), neuropathy 
(51.2%), and hypersensitive reaction (19.5%) was observed [88]. 
Overall, Genexol-PM® showed a similar response to Taxol®, which 
initiated the fast track approval through 505(b)(2) for new drug appli-
cation (NDA) regulatory pathway for Cynviloq® in the U.S [89]. Pacl-
ical® developed by Oasmia Pharmaceuticals, which is composed of 
XR-17, a vitamin A derivative which is made of N-(all-trans reti-
noyl)-L-cysteic acid methyl ester sodium salt and N-(13-cis reti-
noyl)-L-cysteic acid methyl ester sodium salt. It forms micelles of 20–60 
nm which encapsulates PTX and is available as a lyophilized powder, 
administered as infusion [90]. Pharmacokinetic profile of Paclical® and 
Abraxane® are similar, suggesting the opportunity for approval of 
Paclical in the treatment of metastatic BC [91]. Nanoxel® from Dabur 
Pharma Limited (India) is available for the treatment of metastatic BC, 
ovarian cancer, NSCLC, and AIDS-related Kaposi’s sarcoma in India. It is 
a micellar solution of size range 80–100 nm, is composed of a 
pH-sensitive copolymer of N-isopropyl acrylamide and vinylpyrrolidone 
monomers which is stable at physiological pH and drug release in an 
acidic environment as tumor microenvironment [92]. Ranade et al. [93] 
demonstrates in phase I clinical trial the MTD to be 375 mg/m2 with a 
linear pharmacokinetic behavior with grade 3 diarrhea and grade 4 
neutropenia adverse effects. However, the same group conducted a 
phase II trial in anthracycline failed advanced metastatic BC patients 
and show though the formulation in comparison to the generic formu-
lation Taxol® has improved overall response rate, being 40% and 
32.3%, the higher incidence of neutropenia of 56.3% versus 50%, higher 
incidence of neuropathy of 12.5% versus 6.3, respectively [92]. Tri-
olimus® from Co-D Therapeutics is a polymeric micellar formulation 
(30–40 nm) composed of PEG-PLA and encapsulates three drugs, PTX, 
RPM (mTOR inhibitor), and tanespimycin (17-AAG, Hsp90 inhibitor) 
[94]. After showing promising preclinical results in xenograft models by 
the synergistic activity of the three actives, this formulation is in the 
process of phase I clinical trial for breast, NSCLC, and angiosarcoma 
[95]. NK105 is a micellar formulation composed of polyethylene glycol 
and modified polyaspartate by esterification with 4-phenyl-1-butanol 
and is about 85 nm in diameter [96]. The core encapsulates 23% 
(w/w) of PTX and demonstrates good drug retention after intravenous. 
administration. This formulation has MTD of about 180 mg/m2 in phase 
I clinical trial with grade 3 neutropenia as the adverse dose-limiting 
toxicity. Pharmacokinetic profile of this formulation in comparison to 
the marketed generic formulation Taxol® has 15 folds higher AUC at the 
recommended dose of 150 mg/m2. However, in phase III clinical trial 
against metastatic BC enrolled patients failed to meet the primary 
endpoint of the study [97]. 
Fig. 2. Graphic representation of structurally varied nanoformulations, polymer nanoparticles, polymer micelles, liposomes, dendrimers, polymer conjugates, al-
bumin nanoparticles, and carbon nanotubes used in cancer therapeutics including TNBC. These nanostructures are able to accommodate small/biomacromolecular 
therapeutics, contrast/imaging, and other agents that imparts therapeutic and/or theranostic properties. 
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3.3. Liposomes 
Liposomes are composed utilizing the lipid bilayer characteristics, 
which allows the formation of spherical vesicles as large as 100–400 nm, 
enclosing an aqueous core. The lipid bilayer being amphiphilic allows 
the interaction of the hydrophilic surface of the lipid with the central 
aqueous core-forming lipid spheres, whereas the hydrophobic region 
can be modified as per drug delivery needs. The ability of drug loading 
both in the aqueous core or lipid bilayer and the possibility of active and 
passive targeting makes liposomes an attractive alternative for re-
searchers. A liposomal PTX-formulation called Lipusu® is communal-
ized by LuyePharma Group in China consists of lyophilized powder of 
PTX solubilized in liposomes made of lecithin and cholesterol in a ratio 
of 87:13 w/w % and is 400 nm in diameter. It is approved in China as 
first-line chemotherapy for ovarian cancer, first-line therapy for NSCLC 
patients not suitable for radiotherapy or surgery, and for BC. Wang et al. 
[98] investigates the anaphylactic effect of the formulation in contrast to 
Taxol® and showed adverse responses such as piloerection, anhelation, 
and syncope, which were not seen in animals treated with Lipusu®. 
Lipusu® showed some milder hypersensitivity reactions [98]. There are 
several ongoing clinical trials (NCT02142790 for metastatic BC and 
NCT02142010 for Lipusu with cisplatin in BC) [99] to evaluate the ef-
ficacy in comparison to other standard regimen. Another liposomal PTX 
formulation (LEP-ETU®) developed by NeoPharm cardiolipin, choles-
terol, and D-α-tocopheryl acid succinate (in the molar ratio 5:5:90) and 
are about 150 nm in diameter. Phase I clinical trial to study the 
dose-limiting toxicities at 325 mg/m2 associated with the treatment of 
LEP-ETU® shows peripheral neuropathy, myelosuppression, and even 
neurotoxicity [100]. Slingerland et al. demonstrate that the pharmaco-
kinetic profile (AUC and Cmax) of LEP-ETU® were similar to Taxol® 
[101]. A phase II clinical trial has conducted to determine the safety and 
efficacy of LEP-ETU® in thirty-five subjects show sensory poly-
neuropathy (3%) and neutropenia (6%). Other than that no significant 
reactions were observed [102]. 
EndoTAG-1® is a PTX formulation developed by MediGene and later 
taken over by SynCore Biotechnology. It is comprised of liposomes 
composed of phospholipid DOTAP and neutral phospholipid DOPC in a 
53:47 M ratio and are about 200 nm in diameter and positive zeta po-
tential of 25–100 mV in a 0.05 mM KCl solution at pH 7.5 [103]. The 
positively charged liposomes promote the PTX uptake into the tumor 
endothelial cells. As a result of which combining antivascular effects 
with conventional chemotherapy may result in increased permeability 
within the tumors [104]. However, preclinical and clinical trial con-
ducted on other types of cancer such as adenocarcinoma, pancreatic 
cancer is shown to cause neutropenia and thrombocytopenia. Efficacy in 
TNBC was evaluated by Awada and coworkers [105], showing results 
from a phase II clinical trial comparing the safety and efficacy of 
EndoTAG-1® with Taxol® in 140 patients, receiving either weekly 
EndoTAG-1® with Taxol® or EndoTAG-1® (twice a week) or weekly 
Taxol®. However, there was no significant improvement in the overall 
survival between the treatment groups (13.0, 11.9, and 13.1 months, 
respectively). Other adverse effects include pyrexia and chills and about 
17.8% discontinued the therapy due to unbearable adverse events. 
Ongoing clinical trials evaluating EndoTAG-1® for treatment of TNBC 
(NCT01537536 and NCT00448305) [106,107]. CAR, a homing peptide 
modified liposomal with fasudil or fasudil-DETA NONOate combination, 
can efficiently concentrate in the lungs [108,109] for the treatment of 
pulmonary arterial hypertension. Additionally, this construct and 
methodology can also be applied with other cancer drugs for the treat-
ment of TNBC that are metastasized to the lungs. 
Researchers have utilized lipid-based nanocapsules to entrap lipo-
philic drug ferrocenyl tamoxifen derivative FcOHTAM and demon-
strated improved antitumor effects in TNBC xenograft model that is 
resistant to tamoxifen treatment [110]. Lipid-based nanoparticles were 
constructed from chemically modified cholesterol-terminated poly 
(acrylic acid) and cross-linked with diamine linkers for active targeting. 
This modification allows a high drug loading capability of doxorubicin 
via this approach exhibiting superior tumor growth inhibition and no 
systemic toxicity in comparison to the free drug in orthotopic TNBC 
murine model [111]. Similarly, liposome vesicles can efficiently 
encapsulate arsenic trioxide (which has dose-limiting toxicity and rapid 
clearance) resulted in enhanced antitumor efficacy than the parent drug 
in an orthotopic murine model with pharmacokinetic parameters and 
efficacy profile [111]. PEGylated liposomal formulation of DOX and 
gemcitabine showed remarkable responses in TNBC patients, however 
adverse effects such as metastasis to the skin have limited its use [112]. 
In an attempt of active targeting, integrin α3 that is overexpressed in 
TNBC models and is known to cause tumor angiogenesis, proliferation, 
therapeutic resistance, and poor prognosis, is attached to the surface of 
PEG-PCL based liposomes. The authors attach a cyclic octapeptide LXY 
(Cys–Asp–Gly–Phe(3,5-DiF)–Gly–Hyp–Asn–Cys) and achieve enhanced 
accumulation of co-administered drugs (DOX and RPM) at the tumor 
site, resulting in improved antitumor efficacy in in vivo TNBC model 
[113]. Active targeting of eEF-2K which has shown to cause tumori-
genesis and is associated with a poor prognosis in TNBC, by neutral 
liposomal siRNA formulation leads to a significant inhibition in tumor 
growth in orthotopic TNBC mouse model [114]. EndoTAG-1 is a 
PTX-loaded liposome formulation for targeting the activated tumor 
endothelial cells has entered Phase III clinical trial after showing 
promising results in contrast to plain drug in TNBC patients [105]. 
Paclitaxel injection concentrate for nanodispersion (PICN) is a 
nanoparticle-based formulation composed of polymer and lipid, 
polyvinyl-pyrrolidone, cholesteryl sulfate, and caprylic acid-forming 
nanoparticle of 100–110 nm, developed by Sun Pharma and approved 
in India for the treatment of metastatic BC. This formulation is castor oil- 
and albumin-free formulation of paclitaxel and alternative for Taxol® 
and Abraxane®. Jain et al. evaluated the efficacy of this formulation in 
comparison to Abraxane in phase II/III clinical study and demonstrate 
similar efficacy and tolerability profile at MTD of 260 mg/m2. Although 
the incidence of most common side effects such as neutropenia, pe-
ripheral neuropathy, and leukopenia was the least at MTD 260 mg/m2 
versus PICN 295 mg/m2 and Abraxane 260 mg/m2, yet there was no 
statistically significant difference between them [115]. In U.S. PICN is in 
phase III clinical trial for the treatment of biliary tract carcinoma 
(NCT02597465) [116] and just finished phase I trial when administered 
alone or in combination with carboplatin (NCT01304303), the results 
are yet to be disclosed [117]. 
3.4. Dendrimers 
Dendrimers are repeating branched monomers arising radially from 
the central core, formed by the polymerization reaction. These den-
drimers are usually 10–100 nm in size with an amphiphilic nature 
having a hydrophobic core and a hydrophilic outer periphery [118]. Due 
to the polyvalent nature of dendrimers like micelles, gene delivery, 
active targeting can also be possible by conjugating ligands or imaging 
compounds. Wang et al. [119] utilizes a fourth-generation poly(ami-
doamine) dendrimers conjugated to antisense oligodeoxynucleotides for 
targeting the vascular endothelial growth factor expressed in TNBC 
cells. The authors report an increased accumulation of dendrimers in 
TNBC-xenograft mouse model with significant reduction in expression 
of vascular endothelial growth factor, in comparison to unconjugated 
nanoparticles. Gene delivery using dendrimers was further displayed, in 
which a third-generation poly(amidoamine) dendrimer was used to 
deliver YTZ3-15 that can knockdown the TWIST1 transcription factor 
and is associated with aggressive behavior, metastasis, and cellular 
migration through an epithelial-mesenchymal transition in TNBC cells 
[120]. 
3.5. Nanoconjugates 
Nanoconjugates are nanoplatforms that are covalent complexes that 
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can bind to multifunctional groups, providing an opportunity to a con-
jugate protein(s) or peptide(s) of interest such that cell- or tissue-specific 
targeting can be achieved [121]. Mittapalli et al. [122] construct an 
ultra-small hyaluronic acid-PTX nanoconjugates of 2–3 nm that can 
target CD44 receptor located on the surface of metastatic cancer. CD44 
receptor-mediated endocytosis results in 10 folds increase in cellular 
uptake and significant improvement in overall survival of animals in a 
TNBC mouse model of the brain metastasized in contrast to the plain 
drug. The multifunctionality of nanoconjugates was further explored 
and demonstrated poly (β-L-malic acid) nanoplatforms was formed by 
conjugation of a 2C5 monoclonal antibody and for active targeting: 
anti-mouse transferrin receptor (TfR) antibody and oligonucleotides 
(MASONs). This approach allows active targeting of EGFR-positive 
TNBC cells, resulting in significant tumor inhibition via the EGFR 
pathway thus controlling tumor progression [123]. A similar nano-
conjugate was constructed utilizing such nanoplatforms and produces 
significant tumor inhibition with no systemic toxicity in TNBC xenograft 
mice. This strategy was employed for active targeting of three oligo-
nucleotides, leading to a significant arrest of EGFR and laminin-411 
which are known to cause tumor growth and angiogenesis [124,125]. 
A folate-drug nanoconjugate of folic acid and tubulysin B hydrazide 
entered into clinical trial for many types of aggressive cancer including 
TNBC subtype [126]. HPMA copolymer–PTX is the first polymer-drug 
conjugate of PTX, developed by Pharmacia Corporation, conjugating 
PTX to HPMA by a tetrapeptidil linker of glycylphenylalanylleucylgly-
cine. Although the formulation has a good aqueous solubility and about 
5% w/w drug loading capacity, it failed to have any difference in 
pharmacokinetic behavior, illustrating that the conjugation did not have 
any significant impact on the drug behavior, though a partial response 
was observed in one of the twelve patients with advanced BC. However, 
clinical studies in phase I was discontinued earlier due to severe 
neurotoxicity observed [127]. Opaxio™ is a polymer drug conjugate of 
PTX conjugated to the poly(L-glutamic acid) at the 2′-hydroxyl position 
of the drug by an ester linkage. It is available as a lyophilized powder 
and has shown beneficial results in preclinical studies. In ovarian tu-
mors, uptake of Opaxio™ was about 5-fold higher than Taxol® with 
prolonged circulation time [128]. After promising preclinical results, 
pharmacokinetic profiling of this compound in comparison to the orig-
inal drug shows prolonged half-life and low renal clearance, however, 
the achieved Cmax was 3 times lower than Taxol® [129]. Also, similar 
dose-limiting toxicity such as neuropathy and neutropenia similar to 
taxane(s) was observed. CT-2103 completed phase II trial for metastatic 
BC [130] and is also being evaluated in combination with carboplatin 
versus PTX and carboplatin in NSCLC patients [131]. ANG 1005 is a drug 
peptide conjugate of angiopep-2 and PTX that binds to the low-density 
lipoprotein receptor-related protein (LRP)-1 which facilities movement 
across the blood-brain barrier (BBB), as LRP-1 is highly overexpressed in 
BBB. In a preclinical model, ANG 1005 has shown therapeutic efficacy 
which has progressed its application in a clinical trial. In phase II trial 
among metastatic BC patients promising results have been achieved 
with the application of ANG1005 to treat peripheral metastatic BC and 
brain metastasis [132]. It is now in phase III clinical trial 
(NCT03613181) [133]. 
3.6. Albumin-based nanoparticles 
The disadvantages associated with Taxol® caused another nano-
technology based PTX formulations to be marketed by Abraxis/Celgene 
with the tradename “Abraxane”. It is a solvent-free colloidal suspension 
that is lyophilized, including six or seven PTX molecules non-covalently 
bonded to form aggregates of 4–14 nm which further aggregates to form 
130 nm in diameter. It was initially approved by FDA in 2005 for met-
astatic BC but has eventually been approved for treating NSCLC, meta-
static adenocarcinoma and pancreatic cancer, either as a single agent or 
used in combination with other first-line treatment [134]. The phar-
macokinetic profile of Abraxane suggests that clearance and volume of 
distribution are significantly higher than the traditional formulation. It 
is well distributed and binds to the tissue and extravascular proteins 
[135]. Preclinical studies demonstrate an improvement in efficacy, in 
contrast to Taxol® and 33% higher tumor accumulation and less toxicity 
[136]. Advantages such as the ease of administration, reduction in some 
of the adverse effects like hypersensitivity reactions, better overall 
response, and survival were achieved. Although, Abraxane shows a 
reduced risk of neutropenia yet increased incidence of neurotoxicity is 
overserved in combination with gemcitabine in pancreatic cancer [137]. 
Additionally, a randomized clinical trial CALGB 40502, suggests that 
toxicity profile for both the treatment groups receiving either PTX or 
nab-PTX weekly has no improvement, in fact, more neuropathy and 
myelosuppression were observed with nab-PTX [138]. 
Clinical trials on BC patients receiving weekly Abraxane shows it is 
well-tolerated and has higher antitumoral activity in contrast to PTX. 
However, grade 4 neutropenia and grade 3 peripheral neuropathy were 
observed as dose-limiting toxicities [139,140]. Gradishar et al. [141] 
conducted a phase III clinical trial on metastatic BC patients with 
Abraxane showing a significantly higher response rate of 33% versus 
19% improvement with Taxol®. However, no significant difference in 
overall survival, which is considered one of the most important pa-
rameters to evaluate clinical efficacy. Another phase III trial treated with 
Abraxane® (125 mg/m2) or Taxol® (80 mg/m2) each given weekly, 
followed by epirubicin/cyclophosphamide, shows significant higher 
PCR especially in the TNBC cohort in comparison to Taxol® (38% vs 
29%). However, Abraxane® was associated with significantly greater 
toxicities such as peripheral sensory neuropathy compared with Taxol® 
(10% vs 3%) [142]. 
3.7. Carbon nanotubes 
Carbon tubes are cylindrical structures made from benzene rings and 
are insoluble in any solvent and thus can be modified chemically to 
become water soluble or can be functionalized with multiple groups. 
This unique nanoneedle shaped and the monolithic structure allows 
passive diffusion to the lipid layer can be multi-functionalized and can 
be considered an important drug carrier for cancer therapeutics [143, 
144]. Carbon nanotubes could be single-walled (around 1–2 nm, one 
layer) or multi-walled (around 5–100 nm, multiple layers), depending 
upon the number of cylindrical layers. Chemical modification of 
single-walled carbon nanotubes via an ester bond yielded a branched 
polyethylene glycol chain to which PTX was conjugated to the 
water-soluble carbon nanotubes. This conjugate exhibited 10 times 
higher tumor uptake than the conventional Taxol® and little toxicity in 
murine 4T1 breast TNBC model. The improved circulation is probably 
because of the PEGylation that resulted in more suppression in tumor 
growth due to the enhanced permeation and retention [145]. Another 
interesting application of these carbon nanotubes is based on photo 
thermal-induced ablation, where nanotubes promote cell membrane 
permeabilization and necrosis, eliminating both tumor mass and BC 
stem cells, suggesting this could be an effective treatment option for 
tumor resistant and preventing recurrence [146]. 
4. Biological and biomimetic nanomedicine 
Active targeting by attaching ligands on nanoparticles enables to 
recognize and bind to receptors on target cancer cells. Such techniques 
were reported conjugating the nano-carrier systems to biomolecules 
including small molecules, peptides, aptamers, and antibodies [147, 
148]. Biological cells such as lymphocytes, macrophages, exosomes, 
erythrocytes, and platelets are used as whole-cell carriers to depot the 
free drug(s) or drug-loaded nanoparticles for a better tumor targeting 
and causing detrimental effects on the cancerous cells (Fig. 3). Fig. 3 
depicts cell and cell-derived drug loaded delivery system efficiently 
deliver therapeutic load to the tumor cells. In the case of whole 
cell-mediated drug delivery, the activated cells or natural cells often 
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recruited at the site of the injury/tumor, express receptors on their 
surfaces, that has affinity for ligands present on the tumor. This process 
causes receptor-ligand interactions that aid in the uptake of the drug 
loaded delivery system by receptor-mediated endocytosis. On the other 
hand, the cell membrane-mediated drug delivery, for example, neutro-
phils are recruited readily at the tumor site as an inflammatory stimulus 
and permeates the endothelium near the tumor site naturally by a 
multistep process: circulation, tethering, rolling, adhesion, and trans-
migration [149] into the circulation, finally infiltrating the tumor cells 
causing activation due to the concentrated cytokines environment. This 
can cause binding of the adhesions molecules, present on the surface of 
the tumors to undergo binding with the receptors on the surface of the 
cell-derived delivery systems. The upcoming sections focus on cells as 
therapeutic carriers and biomimetic (cell membrane clocked) nano-
particles for tumor directed delivery applications. 
4.1. Hematopoietic stem cells as carrier for targeted delivery 
The remarkable characteristics of hematopoietic stem cells give rise 
to other blood cells. It makes them an appropriate fit for an efficient drug 
delivery system in nanomedicine. These blood cells can be broadly 
divided into three main categories: erythrocytes or red blood cells 
(RBCs), leukocytes (WBCs), and thrombocytes (platelets). These hemo-
cytes play an important role in the defense mechanism of the body 
against a wide range of pathogens and foreign particles. The biological 
drug delivery system (using blood cells as drug carriers) ensures the 
biocompatibility and biodegradability of the nanoparticle-loaded cell 
carriers. The biochemical characteristics favor the non-immunogenicity 
of blood cells guaranteeing successful drug delivery at target sites [150]. 
Thus, blood cells serve as the natural biological carriers that can bypass 
the immune surveillance and efficiently deliver the drugs to target cells. 
Some of the hematopoietic stem cells based nanocarriers that have 
shown clinical potential in various cancer model has been summarized 
in Table 1, with closer attention given to BC and their associated met-
astatic regions [151]. 
4.1.1. Erythrocytes 
Erythrocytes or RBCs are the ideal biological carriers for nano-
medicine that can operate without inducing immunological response 
and provide numerous advantages such as long circulation time, abun-
dant surface ligands, and flexible morphology. RBCs are the most 
abundant cells in the blood (a quarter of the total volume) readily 
transporting oxygen and carbon dioxide throughout the body. These 
biconcave discoid cells (diameter, ~7 μm) have high drug loading ca-
pacity. Due to their extremely high half-life (over 100 days), it is highly 
distinguished from macromolecular structure-based drug delivery sys-
tems. The presence of carbohydrates, proteins, and phospholipids on the 
outer member layer provides stability and deformability allowing to 
target even extremely small vascular structures [152–154]. The eryth-
rocyte membrane undergoes reversible changes between expanded and 
tight network structural integrity and aids in the process of evading 
intravascular hemolysis [155]. 
This delivery system involves the controlled opening of the RBC 
membrane, the encapsulation of the nano-carrier loaded anti-cancer 
drugs, and the subsequent resealing of the outer membrane. For 
example, it encapsulates anti-cancer drugs such as daunorubicin for 
leukemia treatment, 5-fluorouracil (methotrexate) [156], and l-Aspar-
aginase (l-ASNase) [157]. Erythrocytes encapsulate and protect 
l-ASNase from degradation, exhibits a longer half-life, increasing the 
efficiency by ten-fold, and reduce the severity of side effects. In another 
study, asparaginase-loaded RBCs serve as ‘bio-reactors’ to deplete 
asparagine, an amino acid required for cancer cell growth, from the 
blood with a tendency of low coagulation disorders and minimum 
allergic reactions [158,159]. A MTX-loaded erythrocyte treatment 
approach can increase the average survival time of mice bearing hepa-
toma ascites tumors by 28.5–42.8% than native MTX [159]. Magnetic 
targeting using an external magnetic field was applied to DOX-loaded 
RBCs which are bound to iron-oxide nanoparticles pre-coated with a 
photosensitizer in the chemotherapy of cancer [160]. The modification 
of the pharmacokinetic and pharmacodynamics parameters of the drug 
by carrier erythrocytes maintains a relatively inert intracellular envi-
ronment, decreased fluctuations in concentration, reduces drug side 
effects. Thus, the molecular mechanisms of erythrocytes make them 
perfect candidates as carriers of convention and new anti-cancer drugs 
[155,161]. 
4.1.2. Leukocytes 
White blood cells (WBCs) or leukocytes are an integral part of the 
Fig. 3. Schematic representation of possible delivery options of therapeutic agents via whole cell recruitment at the tumor sites. Improved interaction, circulation, 
penetration, and recruitment of cells/cellular vehicles in tumors. 
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Table 1 
Summary of various hematopoietic cells based nanocarriers for breast cancer treatment.  




Membrane coated on PLGA nanoparticles, low-dose irradiation. Subcutaneous model 
using: MKN45 cells. 
Nanoparticles caused 56.68% tumor inhibition, liver 
accumulation in 96 h while LDI caused more tumor 
accumulation with ~89% tumor inhibition. 
Monocytes [132] pH-responsive amphiphilic copolymer, polyethylene glycol-block-poly 
[(1,4-butanediol)-diacrylate-ß-N,N-diisopropylethyl-enediamine] 
(PDB) and phagocyting this in Ly6Chi monocyte isolated from 
peripheral blood. 
Metastatic 4T1 BC. 2 folds increase in tumor accumulation was observed 
with the monocyte loaded nanoparticles, with relatively 
less nonspecific uptake in lung and liver, compared to 
blank nanoparticles (no monocytes). Also, highest AUC 
was observed 7.20-folds higher than PTX, with highest 
tumor suppression of 96.8% over only 50.4% inhibition 
was attained with nanoparticles (without monocytes). 
Also, lung metastasis decreased by 99.2% with these 





A synthetic peptide with dendritic disulfide conjugate of PTX coupled 
with PEG via click reaction, to yield a redox-responsive micelle that 




The micelles were recruited to the surface of the activated 
platelets, due to overexpression of P-selectin on the 
platelets and adhere to it. 
Relative to PTX these targeted micelle exhibits enhanced 
targeting to the primary TNBC tumors as well as lung and 
liver metastasis. This is due to the interaction between 
activated platelets and ICAM overexpressed at the 





Nanogel with TNF- α, RGD peptide (Nanoparticle 1). Dextran 
nanoparticles with coated with platelet membrane with PTX 
(Nanoparticle 2) 
TNBC tumor using 
MDA-MB-231 cells. 
Nanoparticle1 induces tumor vascular inflammation and 
RGD peptide caused significant accumulation in the 
tumor by 5 folds, relative to nanoparticles without RGD. 
Whereas nanoparticle2 cause greater tumor 




Thermo-responsive hybrid nanoparticle composed of poly 
(caprolactone)-ester endcap polymer (PCL), 
dipalmitoylphosphatidylcholine (DPPC) poloxamer 188 and 
membrane coating. 
4T1 orthotropic tumor 
mimicking metastasis 
BC. 
A 12.3, 2.6- and 3-folds increase of fluorescent dye (DiR) 
at the tumors, liver and lung metastasized sites, 
respectively in comparison to free DiR. 69.2% and 12.6% 
tumor inhibition were achieved by the nanoparticles, PTX 
respectively, in comparison to control. Also, 98.6% lung 
metastasis was achieved. 
RBC membrane 
[239] 
PCL, poloxamer 188, co-administrated with the tumor penetrating 
peptide, iRGD and membrane coating. 
Metastatic 4T1 breast 
tumor model. 
The half time of the cell membrane nanoparticles was 
32.8 h (5.8 and 16.9 folds higher than that of polymeric 
nanoparticles and Taxol, respectively). These 
nanoparticles in combination with iRGD yield 2.89, 3.02 
folds higher tumor fluorescence uptake, 90% tumor 
growth inhibition and 94.8% lung metastasis were 
achieved. All comparisons were with uncoated 
nanoparticles with iRGD and cell membrane 
nanoparticles (without iRGD). 
RBC membrane 
[240] 
Ferric oxide (Fe3O4) and O-carboxymethyl chitosan (CMC) 
nanoparticles co-encapsulated PTX and doxorubicin with Arg-Gly-Asp 
(RGD) and membrane coating. 
Subcutaneous xenograft 
model of lung 
carcinoma. 
Synergistic effect of RBC membrane magnetic 
nanoparticles and RGD ligand, on the application of 
magnetic field, increased fluorescent uptake at the 
excised tumors by ~17 times and significant tumor 
reduction in contrast to naked nanoparticles (without 
membrane coating and RGD). 
RBC membrane 
[241] 
DSPE-PEG-MAL coupled with tumor-penetrating bispecific 
recombinant protein (anti-EGFR-iRGD) with RBC membrane coating. 
Subcutaneous tumors of 
gastric cancer cells: 
MKN45. 
RBC membrane coating prolonged nanoparticle 
circulation in the tumors from 2 to 48 h. The synergistic 
effect of anti-EGFR-iRGD along with membrane coated 
nanoparticles caused tumor inhibition by 61% in contrast 




RBC membrane coated nanoparticles. Mammalian intestinal 
mucosal cells (MDCK- 
MDR1) 
Permeability was enhanced by 3.5-& 16.2 folds than free 
PTX in MDCK-MDR1 cell monolayers and intestinal 
mucosa, respectively. The presence of the RBC membrane 
prolonged the circulation time by increasing the mean 
residence time of the nanoparticles by 1.81 folds, AUC by 




pH sensitive polymer cationic 2- aminoethyldiisopropyl with IGF1R 
targeting peptide, after PEGylation and macrophage membrane. 
Orthotopic BC: MDA- 
MB-231 cells. 
Significantly tumor accumulation and towards the center 
of the tumor was achieved, relative to group without the 
non-pH sensitive polymer and without macrophage 
coating, due to membrane coated tumor homing effect 
and pH-sensitive drug release by the polymer. The 
peptide also enhanced the fluorescence intensity due to 
IGF1R mediated uptake pathway. 
Neutrophil [242] CXCL1 chemokine laden thermosensitive hydrogel of PLGA-PEG-PLGA 
nanoparticles, encapsulated by the endogenous neutrophils. 
B16F10 murine 
melanoma cells. 
Neutrophils sequester the nanoparticles and in 8 h shows 
82.2% uptake implying viability of neutrophils were not 
affected by the PTX loaded nanoparticles. Fluorescent dye 
(DiD)increased significantly at the tumor site with CXCL1 
from 1 to 8 h, unlike without the CXCL1 group, suggesting 
the presence of the chemokine was primarily causing 
(continued on next page) 
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innate immune system of the body in response to pathogen invasion. 
When tissue damage, bacterial, and viral infections occur, leukocytes are 
deployed in circulation to combat those changes. Therefore, inflamma-
tion can be defined as a defense mechanism of the body to fight foreign 
invaders (physical, chemical, antigens) and maintain homeostasis 
[162]. Owing to their aiming movement and transmigration ability, 
leukocytes are specifically targeted to deliver nanotherapeutics into 
diseased tissues. The pathogenesis of most types of cancers is in corre-
lation to uncontrolled inflammation. Thus, hijacking leukocytes and 
deploying them as delivery vehicles to transport anti-cancer therapeu-
tics across blood vessel barriers directly to the tumor microenvironment 
are explored [163–165]. 
4.1.3. Neutrophils 
Neutrophils are first-line defenders reaching at the inflammatory site 
(s) migrating across the endothelial layer (neutrophil transmigration) to 
fight pathogens and initiate a phase of repair. They are the most abun-
dant white blood cells (50–70%) in humans and are associated with 
tumor progression as well as tumor inhibition process. The neutrophils 
that infiltrate tumor sites are called tumor-associated neutrophils 
(TANs) [165,166]. The recruitment of TANs into tumor environment is 
mediated by their surface protein composition and chemokine activity. 
TANs are classified as Pro-tumorigenic (N2, produced in the tumor 
microenvironment) and anti-tumorigenic (N1, ability to kill tumor cells) 
which are phenotypically distinct from normal circulating neutrophils. 
Targeting these neutrophils would allow better specificity and enhanced 
therapeutic efficacy of anti-cancer nanotherapeutics [167,168]. Studies 
have shown that inhibition of BM and ECM breakdowns by TANs 
derived NE and MMP-9 can dramatically reduce tumor angiogenesis and 
lung adenocarcinoma in a murine model [169]. In another study, the 
successful downregulation of a murine model tumor ICAM-1 expression 
via shRNA reduced colorectal adenocarcinoma by 45%. In cancer 
treatments, where surgical resection has negative outcomes, anti-TAN 
therapy serves a potential approach with higher disease-free survival 
rates [170,171]. In a recent study, Chu et al. [172] demonstrated gold 
nanorods (GNRs) linked with anti-CD11b Abs were able to exponentially 
decrease tumor growth and increased survival rates in a lung carcinoma 
model of mice. Photothermal therapy was undertaken as the therapeutic 
method because GNRs can absorb infrared light to generate local heat to 
destroy the tumor [172]. In one of their previous studies, they combined 
TA99 monoclonal antibodies and albumin nanoparticles to treat mela-
noma in a mouse model. This was achieved through the mechanism of 
antibody-dependent cellular cytotoxicity, wherein the albumin NPs 
were loaded with photodynamic therapy agents which activated the 
infiltration of neutrophils into tumor sites markedly reducing tumor 
growth and thus emerging as a novel strategy for immunotherapy in 
cancer treatment [173]. Neutrophils have been heavily employed as 
immune cell carriers for delivering nanoparticles to inflammation sites. 
For example, piceatannol-loaded and TCPA-1/cefoperazone acid-loaded 
albumin nanoparticles with neutrophils as delivery vehicles are used as 
treatment approaches for acute lung injury and pyropheophorbide-a 
loaded albumin nanoparticles are targeted against melanoma [165]. 
Therefore, neutrophil-mediated delivery of nanotherapeutics has 
immense potential to dramatically increase target specificity, thera-
peutic efficacy, and provide a translational effect. Their intrinsic prop-
erties of transmigration, ability to infiltrate in huge numbers in response 
to inflammation, and their first responder nature makes them appro-
priate biological carriers to deliver nanotherapeutics [165]. 
4.1.4. Monocytes/macrophages 
Monocytes are an integral part of immune-oncology with the unique 
characteristic to be able to differentiate into tissue macrophage, known 
as tumor-associated macrophages (TAMs), after crossing the endothelial 
barrier. The ability of TAMs to reach the hypoxic areas of the tumor 
microenvironment makes them excellent targets for a biomimetic based 
delivery system. TAMs constitute 70% of the cell mass in breast carci-
noma and can be classified into M1 and M2 types. M2-like macrophages 
are responsible for tumor growth and progression whereas M1 pheno-
type is associated with killing tumor cells. Owing to their innate 
phagocytotic capability, monocytes can be loaded with a variety of 
nanotherapeutics and serve as “Trojan Horse” delivery vehicles reaching 
otherwise inaccessible tumor regions. Once these cells reach the tumor 
sites, they differentiate into macrophages and their nanoparticle-based 
therapeutic function could be initiated by near-infrared illumination, 
henceforth destroying the TAMs associated with tumor metastasis [165, 
174–177]. In a recent study, Choi et al. [178] demonstrated that the 
tumor’s natural recruitment of monocytes may be exploited for 
nanoparticle-based drug delivery and therapeutics. To avoid any harm 
to surrounding cellular entities of the host, the drug was loaded in Au 
nanoshells, nanoparticles consisting of a silica core surrounded by a thin 
Au shell. Human breast tumor spheroids (T47D) were utilized as a model 
to examine the therapeutic efficacy and cellular uptake of the Au 
nanoshells. They successfully demonstrated the potential of monocytes 
as delivery vehicles into hypoxic tumors and established a foundation 
for a novel drug delivery system [178]. 
Poor efficiency of conventional drug delivery systems into the sites of 
metastases leads to high mortality rates of BC. In a recent anti-metastasis 
therapy study, He et al. [179] demonstrated that loading 
Table 1 (continued ) 
Cell type Nanoparticle Core Intended use Targeted cancer type and benefits achieved 
recruitment of the neutrophil loaded nanoparticles. 
Synergistic effect of CXCL1 and neutrophil loaded 
nanoparticles caused the most tumor inhibition of 
67.28%, 2.13 folds higher without the CXCL1 group 
(46.95%). 
Neutrophil [243] Cationic liposomes made of 1,5-dioctadecyl-N-histidyl-L-glutamate 
(HG2C18), internalized in mouse bone marrow derived neutrophils. 
G422 glioblastoma 
cells. 
Highest fluorescent intensity of DiR dye was observed 
with neutrophil nanoparticles in the tumor region of the 
brain collected from surgically treated glioma tumors. 
The nanoparticles migrated to the infiltrating glioma cells 
GFP-G422 cells, up to 96 h, suggesting enhanced 
targeting due to neutrophil which causes inflammatory 
response after surgery. AUCbrain was the highest 
suggesting highest targeting efficiency due to 
neutrophils. 
Neutrophil [244] Commercially available PTX formulation: Abraxane dispersed within 
human NEs in combination with radiotherapy by 5-Gy. 
Gastric cancer: SNU719 
tumor-bearing mice. 
Tumor reduction was maximum when radiotherapy and 
neutrophil nanoparticles were combined. The radiation 
disrupts the tumor and allows the neutrophils to be 
homed at the tumor site, due to the release of 
inflammatory cytokines. Radiation therapy with only 
neutrophil (no nanoparticle) did not produce any 
significant anti-tumor effect.  
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legumain-activated nanoparticles into inflammatory monocytes can 
actively target lung metastases of BC and inhibit tumor progression. The 
self-assembled poly(styrene-co-maleic anhydride) nanoparticles were 
conjugated with a legumain-sensitive peptide and loaded into Ly6c +
inflammatory monocytes (M-SMNs). In this biomimetic delivery system, 
the SMNs would remain inactive until they come in contact with the 
metastatic niche. This prevents early drug release and ensures the living 
state of monocytes which is required for the efficient anti-metastatic 
effect. Upon reaching the tumor microenvironment, the monocytes 
differentiate into macrophages to release the anti-cancer drug as free 
drug molecules by destroying the macrophages. The study shows plau-
sible evidence of inhibition of the proliferation, migration, and invasion 
activities of metastatic 4T1 TNBC cells [179]. In another study, a mouse 
macrophage-like cell line was used to demonstrate the anti-cancer effi-
cacy of lung metastasis of BC (4T1 cells). A mouse macrophage-like cell 
line (RAW 264.7) with similar functions to primary macrophage cells 
were used as delivery vehicles and loaded with DOX to serve as an 
anti-cancer biomimetic delivery system. The DOX loaded macrophage 
system showed tumor suppression, metastasis inhibition, with an 
increased life span of the host and reduced toxicity to other healthy 
tissues and organs as compared to their control groups. Thus, DOX 
encapsulating macrophages proved to be an efficient delivery system 
into tumor sites and showed an enhanced therapeutic effect by inhibit-
ing tumor growth to a great extent [180]. Exploiting autologous mac-
rophages (MΦ) for anti-cancer therapy has been developed in the late 
20th century and it still has unexplored areas to venture upon. Tumors, 
however, promote normal MΦ functions of tissue repair, resulting in 
tumor growth, over inflammatory responses. In the tumor microenvi-
ronment, the replacement of MΦ with genetically engineered monocytes 
or drug-loaded monocytes can be potential delivery vehicles for nano-
therapeutics [181–183]. The encapsulation of drugs in MΦ has an added 
advantage of an extended half-life, protected from clearance by the 
endogenous RES system. The multi-faced benefits of utilizing MΦ as 
delivery vehicles have been demonstrated in a study by Escobar et al. 
[182] They used a spontaneous BC mouse model (MMTV-PyMT), 
wherein they performed hematopoietic stem cell transplants with se-
lective expression of IFNα in TIE2+ tumor-associated MΦs in the model. 
The highly localized TIE2+-MΦ-mediated delivery of IFNα reduced lung 
metastatic areas 5-fold and primary tumor size 3-fold without apparent 
toxic effects to the host organism. The plasticity and versatility of 
autologous macrophages make them ideal candidates for novel drug 
delivery systems to enhance the specificity of cell therapeutics 
[181–183]. 
4.1.5. Thrombocytes 
Platelets are nucleated, small subcellular fragments of megakaryo-
cytes with a half-life of 7–10 days that circulate in the bloodstream and 
are activated during a vascular endothelial dysfunction or damage 
[184]. They are associated with inflammatory cells and play a central 
role in the cancer microenvironment by cell-cell communication and 
ability to uptake a plethora of different molecules [185–187]. Activated 
platelets are key contributors to tumorigenesis, metastasis, tumor 
growth, and angiogenesis. B-thromboglobin and P-selectin, markers of 
platelet activation, are abundant in patients with BC/TNBC, suggesting 
tumor cell-induced platelet aggregation [188]. Once activated, these 
platelets facilitate cancer cell survival and their adhesion to the endo-
thelium. Thus, tumor-associated platelets can be potential therapeutic 
targets and serve as effective delivery vehicles in anti-cancer treatment 
modalities [188,189]. Targeting specific platelet receptors and 
tumor-associated platelets has become an emergent field of delivery of 
anti-tumor therapeutics. Zhang et al. [190] designed a biocompatible 
liposomal nanoparticle with a tumor-homing peptide on the surface and 
loaded with the reversible platelet inhibitor ticagrelor, known as 
CREKA-Lipo-T, to demonstrate its ability to block tumor cell acquisition 
of an invasive phenotype and tumor cell adhesion of platelets. The target 
specificity and therapeutic efficiency of CREKA-Lipo-T was sucessfully 
acheived using 4T1 solid tumors [190]. In another study by the same 
group, they constructed a polymer-lipid-peptide-based drug delivery 
system (comprised of matrix metalloproteinase 2 (MMP2)-cleavable 
peptides, lecithins, and PEGylated phospholipids to form an 
enzyme-responsive drug release known as PLP-D-R) to co-deliver a 
platelet-depleting antibody (R300) and chemotherapeutic drug, DOX. 
They successfully demonstrated the anti-cancer efficacy of PLP-D-R in an 
MCF7 tumor-bearing nude mouse model that showed enhanced tumor 
suppression with minimal bleeding complications. Moreover, they also 
showed enhanced nanoparticle retention (almost thrice as compared to 
control groups), tumor regression, and metastasis inhibition in 
tumor-associated platelet depleted models of mice [146,147]. 
Novel strategies involving anti-platelet therapeutics are gathering 
momentum and emerging as an alternative approach to conventional 
anti-cancer modalities. In a recent study, it was demonstrated that the 
administration of low-dose aspirin, a member of nonsteroidal anti- 
inflammatory drugs which inhibit prostanoid biosynthesis by inhibit-
ing the action of COX-1 and COX-2, reduced the formation of lung me-
tastases [148,191]. It was also shown that in P2Y12-deficient mice, 
which is an ADP platelet receptor, the co-administration of the drug 
clopidogrel with aspirin attenuates the development of hep-
atocarcinoma and improves survival rates of the host [192,193]. In a 
murine model of lung cancer, it was shown that how blocking the 
platelet GPIIb/IIIa receptor, using the monoclonal antibody 10E5, pre-
vented the cells from metastasizing [194,195]. The curative effect of 
heparin and fondaparinux against tumor cells was demonstrated by in-
direct inhibition of thrombin and Factor Xa, thereby inhibiting the 
activation of platelets by BC cells [151]. Additional studies [196–198] 
designed nano construct that can bind simultaneously to GPIIb-IIa like 
integrins and P-selectin on the high-metastatic MDA-MB-231 human BC 
cells. They successfully achieved their goal of killing the tumor cells and 
enhanced the therapeutic efficiency by their platelet-inspired meta-
stasis-targeted drug delivery approach. All the above studies establish 
the potential of utilizing platelets as delivery vehicles and the promising 
future of platelet-inspired anti-cancer therapeutics. 
4.2. Cell-membrane coated nanoparticles for targeted delivery 
Cell membranes isolated from the parent cells are subjected to a 
continuous process, to isolate the various cellular components. Cells are 
previously treated with hypotonic buffer under the protection of pro-
tease inhibitors are followed by series of ultracentrifugation. This en-
ables the removal of cell contents, including enzymes, nucleus, and 
other cellular components. The membranes are then coated on the sur-
face of the nanoparticle core, via extrusion, sonication, and/or electro-
poration techniques (Fig. 4). 
An array of various techniques that could be employed to isolate 
membranes from the source cells by different methods: sonication, the 
freeze-thaw method, extrusion by differential centrifugation, hypotonic 
lysis buffer and/or Dounce homogenization to generate the empty cell 
membrane vesicles. Such strategies would also efficiently minimize off- 
targeting problems, maximize the therapeutic window and would 
ensure maximum survival rate and improve the quality of the patient’s 
life. These systems can show enhanced specificity for cancer cells with 
minimal side-effects, increasing the therapeutic efficacy up to 100-fold 
against drug-resistant cancer stem cells [148]. The reappearance of 
cancer after a post-treatment and disease-free period is the result of 
inappropriate drug targeting and low cancer selectivity [192,194]. 
Thus, the application of nano-carriers for active targeting in cancer drug 
delivery will exponentially alleviate the non-specific accumulation of-
fering enhancement of therapeutic efficiency [147,151]. The distin-
guished physical and chemical properties of these nanoparticles make 
them the appropriate drug delivery carriers. These include their rigidity, 
hydrophobicity, size, and charge, which facilitates their penetration into 
biological barriers and effectively delivers the drug at tumor sites [196, 
199,200]. These approaches have allowed alteration in the 
P. Chowdhury et al.                                                                                                                                                                                                                            
Bioactive Materials 6 (2021) 3269–3287
3280
pharmacokinetics and biodistribution of the drug [199]. The previous 
issues of poor solubility and low bioavailability of the conventional 
anticancer drugs have been overcome by nano-formulating them [201]. 
They can not only conjugate the required targeting therapeutic agents 
but can also deliver it without compromising its activity [202]. This 
makes nanotechnology one of the best man-made achievements of 
recent times. It has changed the face of diagnosis and treatment of fatal 
diseases. The upcoming sections focus on cells as therapeutic carriers 
and biomimetic (cell membrane cloaked) nanoparticles for tumor 
directed delivery applications. 
Different types of source cells are employed to generate empty cell 
membrane nanovesicles that are extracted from either erythrocytes/ 
RBC, leukocytes: neutrophils, monocytes/macrophages, T-lymphocytes, 
thrombocytes/platelets, mesenchymal stem cells, and cancer cells. 
These membrane-derived vesicles retain the surface protein, antigens 
from the source cells when coated on the surface of nanoparticles, can 
directly target or bind to the target site of cancer (Fig. 5). The cellular 
biomembranes impart a double layer, owing to the structure of the lipid 
bilayer and are about 50–800 nm in size [203,204]. The transmembrane 
proteins and all the relevant membrane-bound antigen required for 
imparting a biological characteristic are preserved on the cell mem-
brane, with no loss in functionality during or after translocating the 
membrane onto the surface of the nanoparticles [205]. This allows the 
nanoparticles to be camouflaged by the cell membranes, preventing 
degradation by the patient’s immune system [206]. The cell membrane 
coated nanoparticles can interact with cells of the targeted site, due to 
Fig. 4. Schematic illustration of the 
preparation of cell membranes and 
cellular membrane-cloaked nano-
particles. Step 1 requires selection of 
appropriate cell type and extraction 
method (sonication, freeze thaw, hypo-
tonic lysis, extrusion, or dounce ho-
mogenization). Step 2 needs removal of 
inherent cellular components. After Step 
2 it is often required to incorporate the 
nanoparticle into the cellular membrane 
immediately, to prevent the cellular 
membrane lacking the intercellular 
components from collapsing.   
Fig. 5. Schematic representation of 
bioengineering of the cell membrane 
cloaked drug loaded nanoparticles. 
Various methods (co-extrusion, micro-
fluidic electroporation, cell membrane 
template polymerization) are present to 
coat or decorate cellular membranes on 
nanoparticles (not shown in this sche-
matic). Depending on the nature and 
type of cell membrane carrier that is 
used the choice of drug could be made, 
ranging from both hydrophilic or hy-
drophobic drug molecules (eg: 
liposomes).   
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the presence of receptors originated from the derived parent cells that 
make them able to deliver therapeutics at these targeted sites [207]. 
Thus, cellular membranes coated nanoparticles offer advantages in 
contrast to plain nanoparticles; such as i) prolonged circulation [208] ii) 
cell targeting [209], iii) circumventing the immune system clearance 
[210], iv) detoxification [211], and v) mediating intracellular commu-
nications via endocytosis, which can be used to deliver microRNA, 
mRNA [212]. However, scalability, production, isolation of these 
membranes for a bulk manufacturing process needs to be addressed for 
better clinical applications. 
4.2.1. Erythrocyte membrane-coated nanoparticles 
Erythrocytes are the most common cell component with a unique 
biconcave discoidal shape, allowing a large volume of therapeutic cargo 
to be loaded. They bear high mechanical flexibility allowing them to be 
able to squeeze through very small blood capillaries even when main-
taining the constant surface area. It can circulate about over 100–120 
days and eventually cleared by the RES [160]. Additionally, they pre-
vent unwanted macrophage uptake, provides specificity to the target, 
extend biocompatibility, biodegradability, and non-immunogenic na-
ture, and limits activation of other competitor cellular components 
[213]. Erythrocytes membrane coated nanoparticles are prepared by 
extracting the membrane from the cellular components, yet preserving 
their original protein antigens, that provides the innate natural targeting 
ability. Researchers have utilized hypotonic solution to extract the 
cellular contents and used the membrane to coat PLGA polymer nano-
particles. This construct demonstrated the prolonged circulation of 72 h 
over non coated PLGA nanoparticles [208] and suppress 98% lung 
metastasis in metastatic BC model. Su et al. [214] demonstrated similar 
results, erythrocytes membrane coated PLGA nanoparticles prolong 
circulation due to protein receptors present on the surface of these 
membranes and also in combination with integrating iRGD that provide 
specific targeting of metastatic breast tumor model. The authors show 
inhibition of more than 90% tumor growth and 95% of the lung 
metastasis with these nanoparticles as they can escape clearance by RES 
and circulate longer. 
Additionally, the presence of tumor penetrating peptide iRGD serves 
as a receptor for lung metastatic sites that overexpress αvβ3 integrin and 
neuropilin-1, which allows the nanoparticle to specifically target and 
penetrate tumors. The authors also report enhanced retention of mem-
brane coated nanoparticles at the metastatic regions, without the iRGD 
peptide, indicating the innate tendency of the erythrocytes membrane 
proteins to accumulate near the metastatic and tumor region [214]. Guo 
et al. [215] developed a nano vaccine utilizing the ability of erythrocytes 
coated nanoparticles to target antigen-presenting cells (especially den-
dritic cells) for induction of cytotoxic T lymphocyte-mediated response 
against tumors. The authors developed PLGA nanoparticles, coated with 
erythrocyte membrane entraps melanoma-associated antigenic peptide 
and targets dendritic cells because of their ability to specifically target 
tumor antigens that promote the secretion of pro-inflammatory cyto-
kines such as TNF-α and IFN-γ and causes enhanced CD8+ T-cell 
response. This novel antigenic peptide delivery system retarded tumor 
growth and suppressed tumor metastasis in a prophylactic, therapeutic, 
and metastatic melanoma model. This illustrates the possibility of using 
erythrocytes derived membranes in the development of biomimetic 
nanoparticles to demonstrate tumor-specific immune response. Hybrid 
nanoparticle infusing two types of bioinspired membranes: erythrocytes 
and platelets for prolonging circulation time and the other for expression 
of adhesion proteins, respectively increases site-specific targetability 
and prevents unwanted macrophage uptake [216]. This study demon-
strates the ability to fuse two different types of cell membrane into one 
nanoparticle construct that will possess individual properties of each 
type of membrane and the endless number of possibilities that could be 
further explored. RBC membrane derived membrane-coated nano-
particles are extensively studied for various applications. A detailed 
overview of advantages and limitation of membrane-coated 
nanoparticles over erythrocytes as carriers has been documented by Xia 
et al. [217]. 
4.2.2. Neutrophil membrane-formed nanoparticles 
Neutrophils are the most commonly found leukocytes in humans. 
They are the first immune cells that migrate to any infected site caused 
by bacteria and virus, to prevent the pathogens from spreading, by the 
release of cytokines/chemokines and ROS production. This response is 
called acute inflammation and involves neutrophil infiltration, which is 
regulated by intercellular interaction due to the presence of adhesion 
molecules on the neutrophils and vascular endothelium [218]. For 
example, researchers have demonstrated how activated neutrophils 
which express integrin β2 binds to the inflamed vasculature that over-
express ICAM-1 [219]. A similar approach of conjugating nanoparticles 
to anti-ICAM-1 has also been explored by various researchers, however, 
the conjugation process did not show significant targeting improvement 
due to the complex tumor microenvironment [220]. Also, the cost 
ineffectiveness makes this strategy less useful and makes avenue for 
exploring the other potential options for novel targeting approach, such 
as cell membrane-based or whole-cell nanoparticles. Gao et al. [221] 
shows how human leukemia HL-60 cells were utilized for generating 
nanovesicles by nitrogen cavitation method, which highly express 
integrin β2 and binds to the inflamed vascular endothelium due to the 
overexpression of ICAM-1 on them. The authors loaded the nanovesicles 
with an anti-inflammatory drug (TPCA-1) to show the ability of these 
nanovesicles to reduce the expression of cytokines TNF-α and IL-6, 
demonstrating their ability to bind to the inflamed vasculature and 
producing an anti-inflammatory effect. Red blood cells were used as a 
control to generate nanovesicles that lacked the expression of integrin β2 
and does not bind to the endothelium, elucidating the utilization of 
neutrophils to deliver therapeutics specifically at inflamed vasculature. 
Another similar study was demonstrated by Kang et al. [222] utilizing 
polymeric nanoparticles coated with the neutrophil membrane to target 
tumor vasculature and metastatic tumor cells in 4T1 BC with lung 
metastasis model. The authors demonstrate PLGA nanoparticles when 
coated with neutrophil membrane and loaded with carfilzomib, a pro-
teasome inhibitor targets the circulating tumor cells or the metastatic 
niche and the inflamed endothelium. Thus, demonstrating the potential 
of polymeric nanoparticle coated with neutrophil membrane can be 
used to inhibit early metastasis and preformed metastasis. 
4.2.3. Monocyte-derived nanoparticles 
Monocytes are circulating white blood cells and play a crucial role in 
the inflammatory response and represent around 10% of leukocytes. 
They differentiate into macrophages or dendritic cells, with the latter 
mainly occurring during the active infection [223]. They also have 
similar roles as neutrophils and platelets in maintaining homeostasis and 
inflammatory response. Monocytes have 1–3 days half-life and could be 
exploited due to their intrinsic targeting ability especially at the 
inflamed vasculature or injury site [224]. Researchers have explored 
monocytes derived nanovesicles and have shown that these serve as 
better drug delivery tools over drug-loaded exosomes for various disease 
conditions. Jang et al. [225] loaded doxorubicin in exosome derived 
nanovesicles and show similar inhibition in tumor growth as a 20-fold 
higher dose of the same drug without causing any systemic adverse ef-
fects. The exosomes nanovesicles possess counter receptors such as 
LFA-1 that has specificity for cell adhesion molecules such as ICAM-1, 
VCAM-1, and E-selectin that is overexpressed on the inflamed endo-
thelium cells, enabling the monocytes to target the circulating cells 
causing the maximal release of the therapeutic cargo at the targeted site 
[225]. On a similar approach, PLGA nanoparticles loaded with doxo-
rubicin and coated with monocytes that express α4β1 integrin and binds 
to the cell adhesion molecules such as VCAM-1 that is overexpressed on 
the metastatic cancer cells have also been explored [226]. Further 
application of monocytes derived vesicles for the theranostic purpose 
has also been explored and has shown to cause significantly higher 
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uptake in the brain for upto 5 h, in contrast to non coated nanoparticles 
[227]. This type of construct has also been explored for delivery of 
siRNA and RNAi, due to the failed attempts to deliver naked RNA which 
gets degraded and cannot pass through the membranes to make it to the 
targeted site. Thus, this construct has improved delivery of RNA mole-
cules which further can go through the process of RNA interference and 
suppress overexpressed oncogenes especially in cancer [228,229]. The 
ability of circulating monocytes to target tumor cells due to the 
expression of protein molecules on the surface of these monocytes, make 
them specific to the cells that prevent cancer progression, metastasis, 
angiogenesis, invasion, migration, and resistance to chemotherapy 
[230]. 
4.2.4. Platelet membrane-coated nanoparticles 
Platelets are small and non-nucleated cytoplasmic body that are 
present actively circulating in the blood. They express a wide variety of 
immune cell receptors and adhesion molecules on their surface, 
responsible for mediating immune response. The platelets have the 
unique ability to be recruited instantaneously at the site of injury or after 
an infection which allows them to bind to the antigens and release blood 
clotting factors that would heal the wound. The presence of these 
various protein antigens on their surface allow immunomodulatory and 
cell adhesion capability. Researchers have utilized platelet membrane 
coated PLGA nanoparticles in two disease models of coronary restenosis 
and systemic bacterial infection to deliver docetaxel and vancomycin, 
respectively. Enhanced therapeutic efficacy was achieved via these 
novel biomembranes inspired polymeric nanoparticles in contrast to 
uncoated nanoparticles. Also, the authors demonstrate the coating 
shields the polymeric nanoparticles from unwantedly up taken by 
macrophages, thus enhancing nanoparticle deposition at the target site 
[231]. DOX loaded in platelet coated liposomes with two peptides: 
GPIIb-IIIa-like integrins and P-selectins expressed on their surface. This 
construct shows enhanced targetability to bind and destroy specifically 
metastatic BC cells over nonmetastatic BC cells in in vitro and in vivo 
models [232]. Platelet coated PLGA nanoparticles that have over-
expression of P-selectin was also used to deliver tumor-specific apop-
tosis-inducing ligand cytokine (TRAIL) and doxorubicin to tumor cells 
due to specificity for CD44 receptors, expressed on the surface of tumor 
cells. Due to the enhanced targetability between the platelet membrane 
and cancer cells, the therapeutic efficacy of TRAIL due to activated 
extrinsic apoptosis is enhanced resulting in increased apoptosis. This 
way the authors synergistically deliver active therapeutics to the tumor 
cells by targeting via both intrinsic and extrinsic pathways, eliminating 
metastatic cells too [233]. Similar approaches were made by synthe-
sizing silica nanoparticles that were further functionalized with acti-
vated platelet membranes and decorated with tumor-specific peptides 
such as TRAIL. This construct was able to specifically target circulating 
tumor cells and prevents unwanted phagocytosis, due to the expression 
of CD47 on the surface of the activated platelets that extends the half-life 
of the nanoparticles. This targeting strategy binds to circulating meta-
static cells and shows significant decrease of lung metastases in meta-
static orthotopic BC mouse model [234]. 
Platelets coated magnetic nanoparticles were applied for theranostic 
applications for both cancer therapy and cancer diagnosis. The authors, 
fabricated Fe3O4 nanoparticles coated with platelet membranes that 
express protein moieties which allows longer circulation and prevents 
immunogenicity. The application of magnetic nanoparticles allow op-
tical absorption that extends to tumor magnetic resonance imaging as 
well as photothermal therapy. This allows enhanced tumor targetability 
along with intrinsic targeting ability from the membrane proteins of the 
platelets also reducing macrophage uptake. Thus, this strategy provides 
the application of bioinspired nanoparticle for personalized medicine in 
various disease states [235]. 
5. Conclusions and future perspectives 
To date, TNBC remains a disease with a poor prognosis and poorer 
patient outcomes because of the disparity in molecular and genomic 
profiles among TNBC patients. Although major advancement has been 
made with targeted therapy for other types of BC, such as for HER2 
positive trastuzumab has proven to be a blessing, yet in the case of 
TNBC, chemotherapy remains the backbone treatment regimen. A ray of 
hope in the advancement of therapy for TNBC had emerged when FDA 
approved the first-ever targeted therapy: PARP inhibitors, olaparib and 
talazoparib in 2018. Although it is only restricted among patients with 
BRCA1/2 mutation, which accounts for only 10–15% among TNBC 
population, extensive research is ongoing leading to positive preclinical 
and clinical outcomes with combination therapy or targeted therapy or 
immunotherapy or ADC. However, a lot of improvement could be ach-
ieved with other novel and/or nano formulation-based therapies that 
could lead to greater hope in enhancing treatment options and health 
outcomes among TNBC patients. 
We present our views and recent development of cell membrane 
cloaked nanoparticles and illustrated their application in cancer thera-
peutics, particularly in BC and TNBC. These bioactive systems can also 
be tested or applied for other tumor types. The selection of cell mem-
brane and composition is critical to achieve a superior tumor targeting. 
The unique properties (escaping the immune system and achieve long 
circulation time, inherent biocompatibility and biodegradability, avoid 
use of pharmaceutical excipients/additives, prolong life span, adhesion, 
and homologous targeting, etc.) of source cells (RBCs, WBCs, platelets, 
stem cells, immune cells, and cancer cells, etc.) can be extended as a 
carrier for delivery of therapeutics. However, these whole cells suffer 
from poor drug/therapeutic loading and its structure is destroyed during 
loading process. Thus, nanoparticles coated with appropriate cellular 
membranes can lead to the development of biomimetic nanoplatforms 
which offers low immunogenicity and superior biocompatibility. The 
prime advantage of these biomimetic nanosystems is retaining the 
cellular vesicle structures (membrane proteins, glycans, and lipids) 
which introduces the whole cell properties to the nanosystems. Such 
biomimetic nanoplatforms have been widely adopted in drug delivery, 
imaging, and anti-cancer research. These data laid a foundation for 
designing personalized medicine. Together, membrane cloaked nano-
particle technology has been matured to improve preparation, yields, 
stabilization, and scaling up process. The futuristic approach may be to 
introduce mixed types of cell membranes on nanoparticles rather from a 
cell as coating components for effective tumor targeting. The reviewed 
literature suggests that therapeutic formulations of membrane cloaked 
bioactive nanoformulations do not show systemic toxicities over free 
drugs. It may be possible that extensive and repeated use of such 
bioactive nanosystems can induce inflammation and alteration of the 
immune system. However, their long term systemic toxicity has not been 
studied in humans. Thus for effective implementation of these bio-
mimetic nanoplatforms in drug delivery systems, it is important to focus 
on their future translation into the clinic. 
Declaration of interest 
Authors declare no potential conflict of interests. 
CRediT authorship contribution statement 
Pallabita Chowdhury: Conceptualization, Methodology, Resources, 
Writing – review & editing, Supervision. Upasana Ghosh: Writing – 
original draft, Writing – review & editing, Supervision. Kamalika 
Samanta: Writing – original draft, Writing – review & editing, Super-
vision. Meena Jaggi: Methodology, Resources, Writing – original draft, 
Supervision. Subhash C. Chauhan: Methodology, Resources, Writing – 
original draft, Supervision. Murali M. Yallapu: Conceptualization, 
Methodology, Resources, Writing – original draft, Writing – review & 
P. Chowdhury et al.                                                                                                                                                                                                                            
Bioactive Materials 6 (2021) 3269–3287
3283
editing, Supervision. 
Declaration of competing interest 
The authors declare that they have no known competing financial 
interests or personal relationships that could have appeared to influence 
the work reported in this paper. 
Acknowledgements 
PC and MMY thank the Alma & Hall Reagan Endowment Fellowship. 
The authors acknowledge the support from Department of Immunology 
and Microbiology, School of Medicine, University of Texas Rio Grande 
Valley to MMY, MJ, and SCC. This work is partially supported by NIH 
grants (R01 CA210192, R01 CA206069 and R01 CA204552). 
References 
[1] A.C. Society, Cancer Facts & Figures 2020, 2020. 
[2] G.K. Malhotra, X. Zhao, H. Band, V. Band, Histological, molecular and functional 
subtypes of breast cancers, Canc. Biol. Ther. 10 (10) (2010) 955–960. 
[3] S. Dawson, E. Provenzano, C. Caldas, Triple negative breast cancers: clinical and 
prognostic implications, Eur. J. Canc. 45 (2009) 27–40. 
[4] W.J. Irvin Jr., L.A. Carey, What is triple-negative breast cancer? Eur. J. Canc. 44 
(18) (2008) 2799–2805. 
[5] K. Collett, I.M. Stefansson, J. Eide, A. Braaten, H. Wang, G.E. Eide, S.Ø. Thoresen, 
W.D. Foulkes, L.A. Akslen, A basal epithelial phenotype is more frequent in 
interval breast cancers compared with screen detected tumors, Canc. Epidemiol. 
Prevent. Biomark. 14 (5) (2005) 1108–1112. 
[6] A.C. Garrido-Castro, N.U. Lin, K. Polyak, Insights into molecular classifications of 
triple-negative breast cancer: improving patient selection for treatment, Canc. 
Discov. 9 (2) (2019) 176–198. 
[7] R. Dent, M. Trudeau, K.I. Pritchard, W.M. Hanna, H.K. Kahn, C.A. Sawka, L. 
A. Lickley, E. Rawlinson, P. Sun, S.A. Narod, Triple-negative breast cancer: 
clinical features and patterns of recurrence, Clin. Canc. Res. 13 (15) (2007) 
4429–4434. 
[8] J. Li, D. Qi, T.C. Hsieh, J.H. Huang, J.M. Wu, E. Wu, Trailblazing perspectives on 
targeting breast cancer stem cells, Pharmacol. Therapeut. 223 (2021), 107800. 
[9] R.E. Mansel, O. Fodstad, W.G. Jiang, Metastasis of Breast Cancer, Springer, 2007. 
[10] D.P. Silver, A.L. Richardson, A.C. Eklund, Z.C. Wang, Z. Szallasi, Q. Li, N. Juul, C.- 
O. Leong, D. Calogrias, A. Buraimoh, Efficacy of neoadjuvant Cisplatin in triple- 
negative breast cancer, J. Clin. Oncol. 28 (7) (2010) 1145. 
[11] F. Le Du, B.L. Eckhardt, B. Lim, J.K. Litton, S. Moulder, F. Meric-Bernstam, A. 
M. Gonzalez-Angulo, N.T. Ueno, Is the future of personalized therapy in triple- 
negative breast cancer based on molecular subtype? Oncotarget 6 (15) (2015), 
12890. 
[12] T. Byrski, T. Huzarski, R. Dent, J. Gronwald, D. Zuziak, C. Cybulski, J. Kladny, 
B. Gorski, J. Lubinski, S. Narod, Response to neoadjuvant therapy with cisplatin 
in BRCA1-positive breast cancer patients, Breast Canc. Res. Treat. 115 (2) (2009) 
359–363. 
[13] A. Di Leo, J. Isola, F. Piette, B. Ejlertsen, K. Pritchard, J. Bartlett, C. Desmedt, 
D. Larsimont, M. Tanner, H. Mouridsen, A Meta-Analysis of Phase III Trials 
Evaluating the Predictive Value of HER2 and Topoisomerase II Alpha in Early 
Breast Cancer Patients Treated with CMF or Anthracycline-Based Adjuvant 
Therapy, AACR, 2009. 
[14] F.-C. Bidard, M.-C. Matthieu, P. Chollet, I. Raoefils, C. Abrial, J. Domont, 
M. Spielmann, S. Delaloge, F. Andre, F. Penault-Llorca, p53 status and efficacy of 
primary anthracyclines/alkylating agent-based regimen according to breast 
cancer molecular classes, Ann. Oncol. 19 (7) (2008) 1261–1265. 
[15] O. Gluz, U. Nitz, N. Harbeck, E. Ting, R. Kates, A. Herr, W. Lindemann, 
C. Jackisch, W. Berdel, H. Kirchner, Triple-negative high-risk breast cancer 
derives particular benefit from dose intensification of adjuvant chemotherapy: 
results of WSG AM-01 trial, Ann. Oncol. 19 (5) (2008) 861–870. 
[16] R. Rouzier, C.M. Perou, W.F. Symmans, N. Ibrahim, M. Cristofanilli, K. Anderson, 
K.R. Hess, J. Stec, M. Ayers, P. Wagner, Breast cancer molecular subtypes respond 
differently to preoperative chemotherapy, Clin. Canc. Res. 11 (16) (2005) 
5678–5685. 
[17] L.A. Carey, E.C. Dees, L. Sawyer, L. Gatti, D.T. Moore, F. Collichio, D.W. Ollila, C. 
I. Sartor, M.L. Graham, C.M. Perou, The triple negative paradox: primary tumor 
chemosensitivity of breast cancer subtypes, Clin. Canc. Res. 13 (8) (2007) 
2329–2334. 
[18] C. Liedtke, C. Mazouni, K.R. Hess, F. André, A. Tordai, J.A. Mejia, W.F. Symmans, 
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[155] F. Pierigè, N. Bigini, L. Rossi, M. Magnani, Reengineering red blood cells for 
cellular therapeutics and diagnostics, Wiley Interdiscipl. Rev.: Nanomed. 
Nanobiotechnol. 9 (5) (2017), e1454. 
[156] P. Yousefpour, A. Chilkoti, Co-opt. Biol. Deliver Drugs, Biotechnol. Bioeng. 111 
(9) (2014) 1699–1716. 
[157] V. Agrawal, J. Hee Woo, G. Borthakur, H. Kantarjian, A. E Frankel, Red blood cell- 
encapsulated L-asparaginase: potential therapy of patients with asparagine 
synthetase deficient acute myeloid leukemia, Protein Pept. Lett. 20 (4) (2013) 
392–402. 
[158] C. Domenech, X. Thomas, S. Chabaud, A. Baruchel, F. Gueyffier, F. Mazingue, 
A. Auvrignon, S. Corm, H. Dombret, P. Chevallier, l-asparaginase loaded red 
blood cells in refractory or relapsing acute lymphoblastic leukaemia in children 
and adults: results of the GRASPALL 2005-01 randomized trial, Br. J. Haematol. 
153 (1) (2011) 58–65. 
[159] M. Hunault-Berger, T. Leguay, F. Huguet, S. Leprêtre, E. Deconinck, M. Ojeda- 
Uribe, C. Bonmati, M. Escoffre-Barbe, P. Bories, C. Himberlin, AP hase 2 study of 
L-asparaginase encapsulated in erythrocytes in elderly patients with P hiladelphia 
chromosome negative acute lymphoblastic leukemia: the GRASPALL/GRAALL-SA 
2-2008 study, Am. J. Hematol. 90 (9) (2015) 811–818. 
[160] M. Hamidi, A. Zarrin, M. Foroozesh, S. Mohammadi-Samani, Applications of 
carrier erythrocytes in delivery of biopharmaceuticals, J. Contr. Release 118 (2) 
(2007) 145–160. 
[161] M. Hamidi, H. Tajerzadeh, Carrier erythrocytes: an overview, Drug Deliv. 10 (1) 
(2003) 9–20. 
[162] R. Medzhitov, Origin and physiological roles of inflammation, Nature 454 (7203) 
(2008) 428–435. 
[163] S.J. Turley, V. Cremasco, J.L. Astarita, Immunological hallmarks of stromal cells 
in the tumour microenvironment, Nat. Rev. Immunol. 15 (11) (2015) 669–682. 
[164] J. Conniot, J.M. Silva, J.G. Fernandes, L.C. Silva, R. Gaspar, S. Brocchini, H. 
F. Florindo, T.S. Barata, Cancer immunotherapy: nanodelivery approaches for 
immune cell targeting and tracking, Front. Chem. 2 (2014) 105. 
[165] X. Dong, D. Chu, Z. Wang, Leukocyte-mediated delivery of nanotherapeutics in 
inflammatory and tumor sites, Theranostics 7 (3) (2017) 751. 
[166] Z.G. Fridlender, S.M. Albelda, Tumor-associated neutrophils: friend or foe? 
Carcinogenesis 33 (5) (2012) 949–955. 
[167] R. Rotondo, G. Barisione, L. Mastracci, F. Grossi, A.M. Orengo, R. Costa, 
M. Truini, M. Fabbi, S. Ferrini, O. Barbieri, IL-8 induces exocytosis of arginase 1 
by neutrophil polymorphonuclears in nonsmall cell lung cancer, Int. J. Canc. 125 
(4) (2009) 887–893. 
[168] E. Di Carlo, G. Forni, P. Lollini, M.P. Colombo, A. Modesti, P. Musiani, The 
intriguing role of polymorphonuclear neutrophils in antitumor reactions, Blood, 
J. Am. Soc. Hematol. 97 (2) (2001) 339–345. 
[169] A.M. Houghton, D.M. Rzymkiewicz, H. Ji, A.D. Gregory, E.E. Egea, H.E. Metz, D. 
B. Stolz, S.R. Land, L.A. Marconcini, C.R. Kliment, Neutrophil elastase–mediated 
degradation of IRS-1 accelerates lung tumor growth, Nat. Med. 16 (2) (2010) 
219–223. 
[170] K. Howard, K.K. Lo, L. Ao, F. Gamboni, B.H. Edil, R. Schulick, C.C. Barnett Jr., 
Intercellular adhesion molecule-1 mediates murine colon adenocarcinoma 
invasion, J. Surg. Res. 187 (1) (2014) 19–23. 
[171] B. Hurt, R. Schulick, B. Edil, K.C. El Kasmi, C. Barnett Jr., Cancer-promoting 
mechanisms of tumor-associated neutrophils, Am. J. Surg. 214 (5) (2017) 
938–944. 
[172] D. Chu, X. Dong, X. Shi, C. Zhang, Z. Wang, Neutrophil-based drug delivery 
systems, Adv. Mater. 30 (22) (2018), 1706245. 
[173] D. Chu, Q. Zhao, J. Yu, F. Zhang, H. Zhang, Z. Wang, Nanoparticle targeting of 
neutrophils for improved cancer immunotherapy, Adv. Healthcare Mater. 5 (9) 
(2016) 1088–1093. 
[174] J.G. Quatromoni, E. Eruslanov, Tumor-associated macrophages: function, 
phenotype, and link to prognosis in human lung cancer, Am. J. Tourism Res. 4 (4) 
(2012) 376. 
[175] R. Leek, R. Landers, A. Harris, C. Lewis, Necrosis correlates with high vascular 
density and focal macrophage infiltration in invasive carcinoma of the breast, Br. 
J. Canc. 79 (5) (1999) 991–995. 
[176] R. Noy, J.W. Pollard, Tumor-associated macrophages: from mechanisms to 
therapy, Immunity 41 (1) (2014) 49–61. 
[177] A. Mantovani, P. Allavena, A. Sica, F. Balkwill, Cancer-related inflammation, 
Nature 454 (7203) (2008) 436–444. 
[178] M.-R. Choi, K.J. Stanton-Maxey, J.K. Stanley, C.S. Levin, R. Bardhan, D. Akin, 
S. Badve, J. Sturgis, J.P. Robinson, R. Bashir, A cellular Trojan Horse for delivery 
of therapeutic nanoparticles into tumors, Nano Lett. 7 (12) (2007) 3759–3765. 
[179] X. He, H. Cao, H. Wang, T. Tan, H. Yu, P. Zhang, Q. Yin, Z. Zhang, Y. Li, 
Inflammatory monocytes loading protease-sensitive nanoparticles enable lung 
metastasis targeting and intelligent drug release for anti-metastasis therapy, Nano 
Lett. 17 (9) (2017) 5546–5554. 
[180] J. Fu, D. Wang, D. Mei, H. Zhang, Z. Wang, B. He, W. Dai, H. Zhang, X. Wang, 
Q. Zhang, Macrophage mediated biomimetic delivery system for the treatment of 
lung metastasis of breast cancer, J. Contr. Release 204 (2015) 11–19. 
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